TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01048411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naja-comp.
Description: homeopathic remedy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s.c. injection of NaCl-solution three times a week
Study: NCT03770182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROLITH
Description: transcranial pulse stimulation (TPS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROLITH
Description: transcranial pulse stimulation (TPS)
Study: NCT00880867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
Study: NCT03630497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration
Study: NCT02842268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
Study: NCT02155595

Intervention type: OTHER
Intervention: 500 without BP treatment
Description: lab tests, X-ray, bone scan or MRI, as needed

Intervention type: OTHER
Intervention: 500 with BP treatment
Description: lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
Study: NCT04002674

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib Oral Capsule
Description: Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
Study: NCT00434096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant (SR141716)
Description: oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration once daily
Study: NCT04141462

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood test
Study: NCT03266562

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: F-18 FES
Description: Evaluate uptake of F-18 FES in breast tissue

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: F-18 FDG
Description: Evaluate uptake of F-18 FDG in breast tissue
Study: NCT04328493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate
Description: Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days
Study: NCT00705575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)
Description: During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren (300 mg)
Description: During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
Study: NCT02504060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-D-glucosamine
Study: NCT03659032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pediatric Manual Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Educational Physical Therapy
Study: NCT02786810

Intervention type: DRUG
Group type: OTHER
Intervention: Sulfur hexafluoride type-a lipid microspheres
Description: Used as a contrast to enhance renal ultrasound
Study: NCT01556646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: 15 to 30mg qd titrated to sodium concentration
Study: NCT02362243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Intervention
Description: Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
Study: NCT04112433

Intervention type: DEVICE
Intervention: PURE EP 2
Description: Enrolled patients receiving cardiac ablation treatment using the current standard of care with additional monitoring and intracardiac electrogram signal collection via the PURE EP 2 system.
Study: NCT03835260

Intervention type: DEVICE
Group type: OTHER
Intervention: Pivot Breath Sensor
Description: The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
Study: NCT04083872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
Study: NCT04006158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED bed
Description: Low risk FDA cleared full body LED bed
Study: NCT02968199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A brief intervention
Description: The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
Study: NCT04103294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cowpea variety #1
Description: two most popular varieties of cowpea currently consumed in the selected geographic area

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cowpea variety #2
Description: two most popular varieties of cowpea currently consumed in the selected geographic area
Study: NCT00782652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nitric oxide
Description: Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitrogen gas
Description: Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
Study: NCT02479919

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim® Active TBS
Description: Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim® Active TBS
Description: Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim® Sham TBS
Description: Sham stimulation
Study: NCT02647034

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01901380

Intervention type: DIETARY_SUPPLEMENT
Intervention: Extensively hydrolyzed casein formula + LGG

Intervention type: DIETARY_SUPPLEMENT
Intervention: Extensively hydrolyzed casein formula + LGG
Study: NCT03068299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care guidance
Description: Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
Study: NCT00643955

Intervention type: OTHER
Intervention: muscle strength
Description: muscle strength
Study: NCT03754699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: During the usual pre-anesthesia assessment (performed between D-30 and D0 of the intervention), the anesthesiologist will deliver to the intervention group patient oral and visual information on:~* the numerical scale of pain ranging from 0 to 10 with examples of perceptions corresponding to each level of the scale (calibration)~* nature of postoperative pain (inflammatory character, dynamic over time)~* average pain level incurred by the intervention~* the difference between anti-inflammatory and opioid analgesics~* principles of systematic treatment and pain anticipation~* principles of overdose and side effects prevention This information is standardized and delivered orally, accompanied by a visual support (patient diary), which will be given to the patient upon discharge from the hospital

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard information
Description: Standard information on pain For patients in the control group the standardized information is based on the SG/DGM/DSS 1/41-2010 scheme of the AFSSAPS-CFETD repository.
Study: NCT03428516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed CPAP
Description: CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto-adjusting CPAP
Description: Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
Study: NCT05933837

Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin I
Description: Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin I
Description: Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.
Study: NCT03331874

Intervention type: DIAGNOSTIC_TEST
Intervention: Reflectance Confocal Microscopy
Description: In-vivo microscope
Study: NCT03898245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: apply tDCS
Description: Intensity 2mA, 20minues, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Intensity 0mA, 40 seconds, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
Study: NCT05169294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Program
Description: Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Home Program
Description: Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Home Program
Description: Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
Study: NCT01611259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab and Lenalidomide
Description: Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
Study: NCT06453590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction.
Description: Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction.
Description: Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.
Description: Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
Study: NCT04037527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
Study: NCT01158625

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change of time of administration
Description: Change of time of administration
Study: NCT03844373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: STOCKHOLM
Description: STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
Study: NCT03360292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher target range
Description: Intervention is using a higher oxygen saturation target range than in routine practice
Study: NCT02362243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Intervention
Description: Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
Study: NCT04313166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu(II)ATSM
Description: cooper-containing synthetic small molecule
Study: NCT03521492

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum vitamin D , calcium , parathyroid hormone and albumin level
Description: measuring serum level of Vit. D, PTH, Calcium, and Albumin levels

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum vitamin D , calcium , parathyroid hormone and albumin level
Description: measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
Study: NCT02737566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care + Financial Incentives
Description: Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Tobacco cessation counseling plus pharmacotherapy.
Study: NCT00529932

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CD133+ infusion
Description: Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: Buffered normal saline will be infused in the coronary artery during an angiography.
Study: NCT02209324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Study: NCT05705102

Intervention type: OTHER
Intervention: Coronary intervention
Description: Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for \<24h.

Intervention type: OTHER
Intervention: Coronary intervention
Description: Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for \<24h.
Study: NCT04047017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg, po, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, q2w
Study: NCT02438566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (Oral)
Description: OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (Intravenous)
Description: IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
Study: NCT02100072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG 1440 nm laser
Study: NCT01132079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cream treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cream treatment